Shares of Abbott Laboratories (NYSE:ABT) have earned a consensus recommendation of “Buy” from the seventeen analysts that are covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $53.45.

Several equities analysts have weighed in on ABT shares. Jefferies Group LLC reaffirmed a “buy” rating and issued a $58.00 target price on shares of Abbott Laboratories in a research report on Thursday, August 3rd. BMO Capital Markets reaffirmed a “hold” rating and issued a $53.00 target price on shares of Abbott Laboratories in a research report on Friday, September 1st. Cowen and Company reaffirmed a “buy” rating and issued a $55.00 target price on shares of Abbott Laboratories in a research report on Thursday, August 17th. TheStreet raised Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Monday, July 3rd. Finally, Zacks Investment Research downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, May 31st.

WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/09/17/abbott-laboratories-abt-receives-average-recommendation-of-buy-from-analysts.html.

Abbott Laboratories (NYSE ABT) opened at 51.76 on Friday. Abbott Laboratories has a 52-week low of $37.38 and a 52-week high of $52.60. The firm’s 50-day moving average is $50.01 and its 200-day moving average is $46.93. The company has a market cap of $89.93 billion, a PE ratio of 72.49 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. The firm had revenue of $6.64 billion during the quarter, compared to the consensus estimate of $6.63 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The company’s quarterly revenue was up 24.5% on a year-over-year basis. During the same period last year, the company earned $0.55 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post $2.49 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be paid a dividend of $0.265 per share. This represents a $1.06 annualized dividend and a yield of 2.05%. The ex-dividend date of this dividend is Thursday, October 12th. Abbott Laboratories’s payout ratio is 149.30%.

In related news, insider Brian J. Blaser sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $50.00, for a total transaction of $750,000.00. Following the completion of the sale, the insider now owns 143,154 shares in the company, valued at $7,157,700. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Stephen R. Fussell sold 196,550 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $49.50, for a total value of $9,729,225.00. Following the sale, the insider now owns 221,488 shares of the company’s stock, valued at approximately $10,963,656. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 218,150 shares of company stock valued at $10,811,179. 0.76% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of ABT. Perkins Capital Management Inc. lifted its stake in Abbott Laboratories by 197.6% during the first quarter. Perkins Capital Management Inc. now owns 83,546 shares of the healthcare product maker’s stock worth $3,710,000 after purchasing an additional 55,471 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in Abbott Laboratories by 33.5% during the first quarter. Nisa Investment Advisors LLC now owns 687,051 shares of the healthcare product maker’s stock worth $30,509,000 after purchasing an additional 172,596 shares during the last quarter. Cypress Capital Management LLC WY lifted its stake in Abbott Laboratories by 37.9% during the first quarter. Cypress Capital Management LLC WY now owns 2,531 shares of the healthcare product maker’s stock worth $112,000 after purchasing an additional 696 shares during the last quarter. Trust Department MB Financial Bank N A lifted its stake in Abbott Laboratories by 1.1% during the first quarter. Trust Department MB Financial Bank N A now owns 29,783 shares of the healthcare product maker’s stock worth $1,322,000 after purchasing an additional 320 shares during the last quarter. Finally, Feltz Wealth PLAN Inc. purchased a new stake in Abbott Laboratories during the first quarter worth approximately $112,000. Hedge funds and other institutional investors own 71.66% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.